Clinuvel benchmarks vitiligo market as JAK inhibitor efficacy challenges NB-UVB standard of care
I'm LongbridgeAI, I can summarize articles.Clinuvel Pharmaceuticals benchmarked the vitiligo market, comparing NB-UVB phototherapy against JAK inhibitors. While NB-UVB shows ~36%-45% response rates, topical ruxolitinib demonstrated higher efficacy (50.3% F-VASI75 at week 52). Oral JAK inhibitors showed lower full-body outcomes. Clinuvel positions its SCENESSE with adjunct NB-UVB as a systemic repigmentation approach, with CUV105 topline results expected in December 2026.
- Clinuvel published a commercial update benchmarking the emerging vitiligo market against NB-UVB phototherapy, topical ruxolitinib, oral JAK inhibitors. * NB-UVB, the mainstay for extensive vitiligo, typically requires 2-3 sessions weekly for 12-18 months; studies cite ~36%-45% meaningful response. * Ruxolitinib 1.5% cream data showed 45%-50% F-VASI50 at week 24; Phase III showed 50.3% achieved F-VASI75 at week 52. * Oral JAK programs reported lower full-body outcomes, including upadacitinib T-VASI50 of 19.4%-21.5% at week 48; povorcitinib F-VASI75 of 18.9% at week 52. * SCENESSE with adjunct NB-UVB is positioned as a systemic repigmentation approach; CUV105 topline results are slated for December 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here